Eurofins

Eurofins CDMO is a global contract development and manufacturing organisation delivering end‑to‑end drug substance and product services for small molecules and biologics.

Eurofins CDMO forms part of the Eurofins BioPharma Services network, a division of Eurofins Scientific, a leading international laboratory group. Operating across Europe, North America and India, Eurofins CDMO offers integrated solutions that enable pharmaceutical and biopharmaceutical companies to accelerate their transition from research to clinical development. Their services are supported by a strong scientific foundation, modern facilities, and regulatory compliance, positioning Eurofins as a trusted CDMO partner.

Key Products and Services

• Drug Substance/API Development & Manufacturing
• Small Molecule Solid‑State Research & Formulation Development
• Analytical Method & Stability Studies
• Sterile and Non‑Sterile GMP Manufacturing (Drug Product)
• Pre‑clinical Services and Clinical Trial Materials
• Clinical Packaging, Label & Logistics Services
• Regulatory Support, including CMC, IND/IMPD and NDA/CTD documentation
• Biologics: Upstream/downstream process development, parenteral dosage forms, lyophilisation, spray‑drying, capsules and tablets
• Project Management and CMC Regulatory Affairs (CMC‑RA)

With a global footprint encompassing thirteen state‑of‑the‑art facilities—alongside deep expertise in highly potent compounds, poorly soluble drugs, biologics and innovative formulation technologies—Eurofins CDMO supports its clients with tailored, science‑driven contract manufacturing and development solutions. Accredited by major regulatory agencies including the FDA, EMA, Health Canada and PMDA, the organisation ensures compliance and reliability across each stage of drug development, helping biopharmaceutical companies bring their therapies to market efficiently.